Objective To study the HLA-DRB1 genotype and their r elation with HBV infection among Han patients in shanxi area. Methods HLA-DRB1 genotyping was conducted in 54 patients HBV infection and 108 health controls, as well as 32 asymtomatic HBsAg carriers by using polymerase ch ain reaction/sequence specific primer (PCR-SSP) method. All the patients, asy mtomatic HBsAg carriers, and healthy subjects were inhabitants of Shan'xi area o f Han nationality. The association between HLA-DRB1 genotype and different repl ication of HBV were also studied. Results DRB1*04,DRB1*09,DRB 1*12, DRB1*15 were the most common genotypes in the Shan'xi Han inbabitants wit h the frequency of 16.2%,12.5%,11.6% and 13.4% respectively. Compared to 108 healthy controls, the allele frequency of HLA-DRB1*03 was 11.1% in HBV patien ts versus 3.7% in healthy controls, with odds ratio=3.57 and Pc=0.014 ( P

AIM: To study the HLA-DRB1 genotype and their relation with HBV infection in Shaanxi Han patients.METHODS: HLA-DRB1 genotyping was conducted in 108 case of chronic HBV infection and 108 health controls as well as 32 asymtomatic HBsAg carriers by using polymerase chain reaction-sequence specific primer method.All the patients,asymtomatic HBsAg carriers and health subjects were residents of Shaanxi district and belonged to Han nationality.The association between HLA-DRB1 genotype and different replication of HBV was also studied.RESULTS: DRB1~*04,DRB1~*09,DRB1~*12 and DRB1~*15 were the most common genotypes in Shaanxi Han residents with the frequency of 16.2%,12.5%,11.6% and 13.4%,respectively.Compared to 108 health controls,the allele frequency of HLA-DRB1~*03(10.6% of HBV patients versus 3.7% of health controls,odds ratio=3.10;P

MicroRNA (miRNA) plays an important role in the development of diffuse large B-cell lymphoma (DLBCL) by binding to the 3′ non-coding region of the target gene mRNA to regulate gene expression after transcription. The expression level of miRNA is closely related to the clinical staging, typing, prognosis assessment, and therapeutic effect of DLBCL. miRNA has a great potential as that of DLBCL-related biomarkers, and because of the close link between the two, miRNA-based therapies are expected to lead to new treatment options for DLBCL patients.

It remains unclear whether heart transplantation is still feasible on patients who develop neurological complications before surgery and underwent successful neurological treatment.This article reported the diagnosis and treatment process of a heart failure patient complicating with acute ischemic stroke,who underwent successful heart transplantation after thrombectomy for acute ischemic stroke,aiming to provide clinical evidence and decision-making plan on diagnosis and treatment options for this group of patients with severe neurological complications.

Objective:To explore the efficacy and safety of domestic bortezomib in combination with lenalidomide and dexamethasone in the treatment of newly diagnosed multiple myeloma (NDMM) .Methods:This multicenter, prospective, single-arm clinical study included 126 patients with NDMM admitted to seven hospitals between December 2019 and January 2022. All patients received domestic bortezomib in combination with lenalidomide and dexamethasone (BLD regimen), and the efficacy, prognostic factors, and safety were analyzed.Results:Among the 126 patients with NDMM, 118 completed four cycles of treatment, with an overall response rate (ORR) of 93.22% (110/118) and a ≥very good partial response (VGPR) rate of 68.64% (81/118). Ultimately, 114 patients completed at least eight cycles of treatment, with an ORR of 92.98% (106/114) and a ≥VGPR rate of 77.19% (88/114). Eighteen patients underwent autologous hematopoietic stem cell transplantation after completing 6-8 cycles of the BLD regimen, with an ORR of 100% (18/18) and a ≥VGPR rate of 88.9% (16/18). The proportion of patients achieving ≥VGPR increased with the treatment duration, and factors such as staging and age did not significantly affect efficacy. Single-factor analysis showed that R2-ISS stage Ⅲ/Ⅳ, blood calcium >2.27 mmol/L, and failure to achieve VGPR after six cycles were adverse prognostic factors for progression-free survival (PFS) ( P<0.05), whereas failure to achieve VGPR after six cycles was an adverse prognostic factor for overall survival (OS) ( P<0.001). Multifactor analysis demonstrated that failure to achieve VGPR after six cycles is an independent adverse prognostic factor for PFS ( P=0.002). The incidence of hematologic adverse reactions was 16.7% (19/114), and nonhematologic adverse reactions were mainly mild to moderate, with no significant cardiac or renal adverse reactions observed. Conclusion:The BLD regimen is effective in treating NDMM, in which patients with high-risk genetic features are still achieving a high ≥VGPR rate, and the overall safety is good.